By demonstrating an MCP-1/CCL2-lowering effect of Empa in HPTCs, we thus present novel evidence for the anti-inflammatory potential of SGLT2i, which might have therapeutic implications beyond attenuating DKD, given the key role of inflammation for non-diabetic kidney disease as well as extra-renal diabetic complications. This evidence concerns the gene CCL2 and diabetic kidney disease.